Cardiff Oncology (CRDF) Invested Capital (2016 - 2025)
Historic Invested Capital for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $48.8 million.
- Cardiff Oncology's Invested Capital fell 121.88% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year decrease of 121.88%. This contributed to the annual value of $82.9 million for FY2024, which is 1894.21% up from last year.
- Per Cardiff Oncology's latest filing, its Invested Capital stood at $48.8 million for Q3 2025, which was down 121.88% from $58.6 million recorded in Q2 2025.
- Cardiff Oncology's Invested Capital's 5-year high stood at $140.4 million during Q4 2021, with a 5-year trough of $48.8 million in Q3 2025.
- In the last 5 years, Cardiff Oncology's Invested Capital had a median value of $86.6 million in 2023 and averaged $92.8 million.
- As far as peak fluctuations go, Cardiff Oncology's Invested Capital soared by 193171.92% in 2021, and later crashed by 3949.11% in 2024.
- Cardiff Oncology's Invested Capital (Quarter) stood at $140.4 million in 2021, then decreased by 24.27% to $106.3 million in 2022, then plummeted by 34.42% to $69.7 million in 2023, then grew by 18.94% to $82.9 million in 2024, then plummeted by 41.18% to $48.8 million in 2025.
- Its Invested Capital stands at $48.8 million for Q3 2025, versus $58.6 million for Q2 2025 and $70.9 million for Q1 2025.